An Overview of Phase 2 Clinical Trial Designs

Area of Science:

• Clinical pharmacology and drug development
• Biostatistics and clinical trial design

Background:

• Clinical trials evaluate new human treatments in phases to assess safety and efficacy.
• Phase 1 trials assess safety and tolerability in small patient groups (20-80) across dose levels.
• Phase 2 trials determine promising efficacy for larger studies and further assess safety in hundreds of patients.

Purpose of the Study:

• To provide an overview of commonly used phase 2 clinical trial designs.
• To emphasize critical elements and considerations for planning phase 2 trials.
• To compare three potential phase 2 designs using the NRG-HN002 trial as a case study.

Main Methods:

• Review of commonly utilized phase 2 clinical trial designs.
• Discussion of critical elements and considerations in phase 2 trial planning.
• Comparative analysis of three distinct phase 2 designs within the NRG-HN002 trial context.

Main Results:

• Identifies and describes prevalent phase 2 clinical trial methodologies.
• Outlines essential factors for successful phase 2 trial design and execution.
• Illustrates practical application and comparison of phase 2 designs through a specific trial example.

Conclusions:

• Understanding phase 2 trial designs is crucial for advancing new treatments.
• Careful consideration of design elements ensures efficient and informative early-stage drug evaluation.
• The presented comparison aids in selecting appropriate phase 2 designs for future clinical research.